Phase II Study With Trastuzumab + Paclitaxel in Locally Advanced HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors

NCT02307227 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: Trastuzumab
DRUG: Paclitaxel
DRUG: Epirubicin
DRUG: Docetaxel

Sponsor

Centro di Riferimento Oncologico - Aviano